(Q33416047)

English

Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

thrombocytopenia

1 reference

based on heuristic

inferred from title

thrombotic thrombocytopenic purpura

1 reference

based on heuristic

inferred from title

author name string

Nan Wu

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jia Liu

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Shangbin Yang

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Eric T Kellett

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Spero R Cataland

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Hong Li

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Haifeng M Wu

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

23 June 2014

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

55

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18-24

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinical practice. Thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Recent advances in thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

How I treat thrombotic thrombocytopenic purpura and atypical haemolytic uraemic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Complement therapy in atypical haemolytic uraemic syndrome (aHUS).

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Diagnosis and management of complement mediated thrombotic microangiopathies

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP.

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Biochemistry and genetics of von Willebrand factor

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

ADAMTS13 turns 3

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

The emerging concept of residual ADAMTS13 activity in ADAMTS13-deficient thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

ADAMTS-13 assays in thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

TTP and ADAMTS13: When Is Testing Appropriate?

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Thrombotic thrombocytopenic purpura: 2012 American Society for Apheresis (ASFA) consensus conference on classification, diagnosis, management, and future research

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and nonidiopathic thrombotic thrombocytopenic purpura.

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

A rapid test for the diagnosis of thrombotic thrombocytopenic purpura using surface enhanced laser desorption/ionization time-of-flight (SELDI-TOF)-mass spectrometry

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Relationship between ADAMTS13 activity in clinical remission and the risk of TTP relapse

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Severe ADAMTS13 deficiency in adult idiopathic thrombotic microangiopathies defines a subset of patients characterized by various autoimmune manifestations, lower platelet count, and mild renal involvement

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Survival and relapse in patients with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Performance of a clinical prediction score for thrombotic thrombocytopenic purpura in an independent cohort.

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Targeting the inhibitor of ADAMTS13 in thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Platelet recovery rate during plasma exchange predicts early and late responses in patients with thrombotic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1111%2FTRF.12762

21 January 2018

Identifiers

10.1111/TRF.12762

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33416047&oldid=1646359190"